Tietoja työnantajasta
The LBI for Lung Vascular Research has substantial expertise in the basic mechanisms of pulmonary vascular constriction and remodelling, combined with a broad and profound clinical background. We aim to provide a significant contribution to early recognition of pulmonary vascular diseases including pulmonary hypertension via novel and non-invasive methods and to develop innovative therapeutic strategies for an improved prognosis and better quality of life for the victims of this serious disease. The integrative, multidisciplinary and translational structure of the LBI-LVR allows it to uncover underlying molecular pathways, identify distinct targets for reverse-remodelling therapy, foster drug development based on these targets, and prove these new treatment options in preclinical and clinical proof-of-concept trials.
All our actions, both in research and implementation, will be based on mutual respect and esteem with regard to the patients, our partners, and our staff.
The main objectives of the LBI for Lung Vascular Research are:
- Exploring mechanisms of pulmonary vascular disease enabling the identification of both novel therapeutic targets and new disease biomarkers that could enable specific diagnosis and therapy monitoring
- Developing new diagnostic tools for non-invasive screening for pulmonary vascular diseases
- Implementing the achieved results into preclinical as well as clinical pilot studies
- Increasing awareness for pulmonary vascular diseases in the society and for healthcare providers